Technical Data
I7661-16J2
Insulin-Like Growth Factor Binding Protein 3, Recombinant, Western Blot Control (IGFBP3, tcag7.703, BP-53; IBP3, IGF-binding protein 3, Growth hormone-dependent binding protein)
50ul
100ul
Molecular Biology Storage: -20CShipping: Blue Ice
The insulin like growth factors (IGFs) are the major growth-promoting factors in the plasma. IGFs are secreted by a variety of cells and exert a multitude of effects on cellular survival, growth and differentiation. The A and B domains of IGFs are identical to insulin. IGF initiates their biological action through binding to the type IGF receptor (IGF-1R), a heterotrimeric protein complex with a tyrosine kinase activity. The IGF-IIR lacks the kinase activity and is actually identical to the mannose-6-phophate receptor. Unlike most other peptide hormones, IGFs are complexed with specific binding proteins in the plasma known IGF Binding proteins (IGFBPs). At least 6 related IGFBPs (IGFBP1-6) have been well characterized. Recently, IGFBP-7/Mac25/prostacyclin-stimulating factor (PSF)/tumor adhesion factor (TAF) was originally identified as a cDNA derived from leptomeninges. These proteins are present in plasma in high concentration as compared to the membrane IGFRs. Therefore, IGFBPs have the potential to modulate the IGF action. IGFBPs have been shown to either inhibit or stimulate the IGF effects. The primary structures of mammalian IGFBPs appear to contain three distinct domains of roughly equivalent sizes: the conserved N-terminal domain, the highly variable mid region, and the conserved C-terminal domain. Human IGFBPs share approximately 36% identity. Recently several groups of cysteine-rich proteins with discrete, but striking, structural and functional similarities to the IGFBPs. This has led to the proposal of an IGFBP superfamily, comprised of the IGFBPs and these IGFBP-related proteins (IGFBP-rP1-9 or IGFBP-8-12).

Source:
IGFBP3 (human 264aa, expressed in NSO cells .

Applications:
Suitable for use in Western Blot as a positve control for I7661-16H2. Other applications not tested.

Recommended Dilution:
Western Blot: 10ul/lane. Heat before loading on gels. If stored for several weeks, add 5ul of fresh 2x sample buffer per 10ul I7661-16J2 before heating. Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage, store at -20C. Aliquots are stable for at least 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Source: IGFBP3 (human, 264 aa) expressed in NSO cells.
Purity: Purified using immunoaffinity chromatography and other purification techniques.
Form: Supplied as a liquid in reduced SDS-PAGE sample buffer.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Cubbage ML et al (1990) JBC 265, 12642-12649; 2. Wood WI et al (1988) Mol. Endocrinol. 2, 1176-1185; 3. Thwatt R et al (1993) DNA seq. 4, 43-46; 4. Zapf J et al (1990) JBC 14892-14898; 5. Hwa V et al (1999) Endocrine Rev. 20, 761-787 (review).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.